HIV infection Infections and Infestations HIV
Conditions
Interventions
Each participant will be randomised to one of the following groups:
Group 1: HAART starting at CD4 levels 250 cells/mm^3
Group 2: HAART starting at CD4 levels 350 cells/mm^3
Sponsors
Institute of Community Medicine, University of Tromsø (Norway)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Treatment naive Human Immunodeficiency Virus (HIV)-infected individuals 2. 16 years of age or older 3. CD4 count between 450 and 250 cells/mm^3
Exclusion criteria
Exclusion criteria: 1. If patient fulfils current indications for immediate treatment: CD4 less than 250 cells/mm^3 or WHO clinical stage 3 or 4 2. If CD4 is currently greater than 450 cells/mm^3 . This is because patient will probably not start Anti-Retroviral Therapy (ART) during the first year to come
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. WHO clinical stage, assessed after one and possibly also after two years of treatment 2. Changes in CD4 count after randomisation and after start of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Weight maintenanace 2. Intercurrent diseases 3. Acquired Immune Deficiency Syndrome (AIDS) development 4. Survival | — |
Countries
Cameroon
Outcome results
None listed